Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 6 studies | 76% ± 25% | |
oligodendrocyte | 5 studies | 25% ± 4% | |
type II pneumocyte | 4 studies | 25% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 51% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 25804.58 | 226 / 226 | 98% | 181.31 | 399 / 406 |
lung | 98% | 596.97 | 566 / 578 | 19% | 1.48 | 221 / 1155 |
pancreas | 97% | 23.43 | 318 / 328 | 2% | 0.15 | 3 / 178 |
thymus | 90% | 9.36 | 586 / 653 | 1% | 0.01 | 4 / 605 |
brain | 87% | 6.87 | 2300 / 2642 | 0% | 0.00 | 1 / 705 |
skin | 68% | 4.37 | 1232 / 1809 | 13% | 0.29 | 59 / 472 |
uterus | 78% | 4.48 | 132 / 170 | 0% | 0 | 0 / 459 |
spleen | 77% | 42.73 | 186 / 241 | 0% | 0 | 0 / 0 |
prostate | 76% | 4.95 | 187 / 245 | 0% | 0.00 | 1 / 502 |
bladder | 71% | 4.48 | 15 / 21 | 3% | 0.28 | 16 / 504 |
ovary | 72% | 5.53 | 130 / 180 | 0% | 0 | 0 / 430 |
adrenal gland | 69% | 3.87 | 179 / 258 | 0% | 0 | 0 / 230 |
peripheral blood | 68% | 38.89 | 631 / 929 | 0% | 0 | 0 / 0 |
stomach | 65% | 2.79 | 234 / 359 | 1% | 0.02 | 3 / 286 |
esophagus | 62% | 3.27 | 893 / 1445 | 2% | 0.07 | 4 / 183 |
kidney | 62% | 2.74 | 55 / 89 | 1% | 0.08 | 8 / 901 |
intestine | 57% | 3.04 | 552 / 966 | 0% | 0.25 | 2 / 527 |
breast | 55% | 4.43 | 254 / 459 | 2% | 0.14 | 19 / 1118 |
blood vessel | 56% | 2.97 | 744 / 1335 | 0% | 0 | 0 / 0 |
adipose | 50% | 6.50 | 597 / 1204 | 0% | 0 | 0 / 0 |
heart | 48% | 2.68 | 414 / 861 | 0% | 0 | 0 / 0 |
muscle | 34% | 1.31 | 270 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 3% | 0.05 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0010757 | Biological process | negative regulation of plasminogen activation |
GO_0003331 | Biological process | positive regulation of extracellular matrix constituent secretion |
GO_0071333 | Biological process | cellular response to glucose stimulus |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0097421 | Biological process | liver regeneration |
GO_0007596 | Biological process | blood coagulation |
GO_0006508 | Biological process | proteolysis |
GO_2000346 | Biological process | negative regulation of hepatocyte proliferation |
GO_0042730 | Biological process | fibrinolysis |
GO_0030163 | Biological process | protein catabolic process |
GO_0051918 | Biological process | negative regulation of fibrinolysis |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004181 | Molecular function | metallocarboxypeptidase activity |
Gene name | CPB2 |
Protein name | Carboxypeptidase B2 (EC 3.4.17.20) (Carboxypeptidase U) (CPU) (Plasma carboxypeptidase B) (pCPB) (Thrombin-activable fibrinolysis inhibitor) (TAFI) Carboxypeptidase B2 |
Synonyms | |
Description | FUNCTION: Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin. . |
Accessions | ENST00000675730.1 ENST00000181383.10 [Q96IY4-1] A0A6Q8PG06 ENST00000674625.1 A0A087WSY5 A0A6Q8PHS9 ENST00000439329.5 Q96IY4 |